Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations.

The interaction of the kappa-opioid receptor with arylacetamide and benzomorphan derivatives acting as agonists was modeled through pharmacophore-based and docking calculations. Potentially bioactive conformations of representative ligands (U-50,488 and its benzo-fused analogues 4 and 6 for arylacetamides and MPCB for benzomorphans) were identified by systematic conformational analysis and docked into a 3D model of the kappa-receptor. The obtained complexes, refined by energy-minimization and molecular dynamics, were evaluated for their consistency with structure-activity relationships and site-directed mutagenesis data. The following interactions are hypothesized to govern the ligand-receptor recognition process: (i) a salt bridge between the Asp138 carboxylate and the protonated nitrogen of the bound agonist; (ii) a hydrogen bond donated by the Tyr312 hydroxyl to the carbonyl oxygen of arylacetamides and MPCB; (iii) hydrophobic interactions established by the dichlorophenyl moiety of arylacetamides and the pendant phenyl ring of MPCB with the surrounding side chains of Tyr312, Leu224, Leu295, and Ala298; (iv) a pi-stacking contact between the Tyr312 side chain and the phenyl ring of arylacetamides; (v) a hydrogen bond linking the His291 imidazole ring to the phenolic hydroxy group featured by typical benzomorphans and the arylacetamides 4 and 6.

[1]  G. Dondio,et al.  Substituted 1-(aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinolines: a novel class of very potent antinociceptive agents with varying degrees of selectivity for kappa and mu opioid receptors. , 1992, Journal of medicinal chemistry.

[2]  M. Menziani,et al.  Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. , 1996, Journal of medicinal chemistry.

[3]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[4]  Gerard F. Costello,et al.  A novel series of potent and selective agonists at the opioid κ-receptor , 1988 .

[5]  G. Dondio,et al.  Selective kappa-opioid agonists: synthesis and structure-activity relationships of piperidines incorporating on oxo-containing acyl group. , 1994, Journal of medicinal chemistry.

[6]  D. Rees,et al.  Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives. , 1988, Journal of medicinal chemistry.

[7]  M. Froimowitz,et al.  Conformational preferences of the kappa-selective opioid agonist U50488. A combined molecular mechanics and nuclear magnetic resonance study. , 1992, Journal of medicinal chemistry.

[8]  F. Allen,et al.  The Cambridge Crystallographic Data Centre: computer-based search, retrieval, analysis and display of information , 1979 .

[9]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[10]  D. L. Larson,et al.  Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. , 1998, Journal of medicinal chemistry.

[11]  J. G. Vinter,et al.  Strategic approaches to drug design. I. An integrated software framework for molecular modelling , 1987, J. Comput. Aided Mol. Des..

[12]  S. Tam,et al.  Synthesis of (1′, 2′-trans)-3-phenyl-1-[2′-(N-pyrrolidinyl)cyclohexyl]-pyrrolid-2-ones as κ-selective opiates , 1990 .

[13]  T. Reisine.  Opioid analgesics and antagonists , 1996 .

[14]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[15]  D. Scopes,et al.  A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. , 1993, Journal of medicinal chemistry.

[16]  P. von Voigtlander,et al.  Benzeneacetamide amines: structurally novel non-m mu opioids. , 1982, Journal of medicinal chemistry.

[17]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.

[18]  M. Sbacchi,et al.  (1S)-1-(aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinoline and heterocycle-condensed tetrahydropyridine derivatives: members of a novel class of very potent kappa opioid analgesics. , 1991, Journal of medicinal chemistry.

[19]  W. Bowen,et al.  Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor. , 1992, Journal of medicinal chemistry.

[20]  L. Pasquinucci,et al.  Non-peptide ligands for opioid receptors. Design of kappa-specific agonists. , 1993, Journal of medicinal chemistry.

[21]  D. Rees,et al.  The design and synthesis of kappa opioid ligands based on a binding model for kappa agonists , 1993 .

[22]  E. J. Simon,et al.  Opioid Receptor Multiplicity: Isolation, Purification, and Chemical Characterization of Binding Sites , 1993 .

[23]  U. Holzgrabe,et al.  Search for the Pharmacophore in Kappa‐agonistic Diazabicyclo[3.3.1]nonan‐9‐one‐1,5‐diesters and Arylacetamides , 1996, Archiv der Pharmazie.

[24]  G. Bell,et al.  Molecular biology of opioid receptors , 1993, Trends in Neurosciences.

[25]  K. Fujibayashi,et al.  Pharmacological properties of R-84760, a novel κ-opioid receptor agonist , 1994 .

[26]  M. Zerner,et al.  A Broyden—Fletcher—Goldfarb—Shanno optimization procedure for molecular geometries , 1985 .

[27]  Rick L. Ornstein,et al.  What Happens to Salt-Bridges in Nonaqueous Environments: Insights from Quantum Mechanics Calculations , 1996 .

[28]  Philip S. Portoghese,et al.  An Analysis of the Conserved Residues between Halobacterial Retinal Proteins and G-Protein Coupled Receptors: Implications for GPCR Modeling , 1996, J. Chem. Inf. Comput. Sci..

[29]  D. Rees,et al.  Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives. , 1990, Journal of medicinal chemistry.

[30]  A. Giordani,et al.  (2S)-1-(arylacetyl)-2-(aminomethyl)piperidine derivatives: novel, highly selective kappa opioid analgesics. , 1991, Journal of medicinal chemistry.

[31]  G. Uhl,et al.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.

[32]  Hugo Kubinyi,et al.  Similarity and Dissimilarity: A Medicinal Chemist’s View , 2002 .

[33]  D. Rees,et al.  CI‐977, a novel and selective agonist for the κ‐opioid receptor , 1990, British journal of pharmacology.

[34]  T. Blackburn,et al.  Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists. , 1991, Journal of medicinal chemistry.

[35]  G. Pasternak,et al.  An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.

[36]  Marina Tintelnot,et al.  Geometries of functional group interactions in enzyme-ligand complexes: Guides for receptor modelling , 1989, J. Comput. Aided Mol. Des..

[37]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[38]  A. Lomize,et al.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.

[39]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[40]  Peter A. Kollman,et al.  Application of the multimolecule and multiconformational RESP methodology to biopolymers: Charge derivation for DNA, RNA, and proteins , 1995, J. Comput. Chem..

[41]  D. Scopes,et al.  A series of novel, highly potent and selective agonists for the κ‐opioid receptor , 1990 .

[42]  W. Bowen,et al.  Synthesis and receptor binding of enantiomeric N-substituted cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamines as high-affinity sigma receptor ligands. , 1991, Journal of medicinal chemistry.

[43]  A. McKnight,et al.  trans N -Methyl- N -[2-(1-pyrrolidinyl)cyclohexyl] cycloprop-2-ene-1-carboxamides: Novel lipophilic kappa opioid agonists , 1997 .

[44]  D. Ringe.  Binding by design , 1991, Nature.

[45]  J. Thornton,et al.  Ion-pairs in proteins. , 1983, Journal of molecular biology.

[46]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[47]  G. F. Steinfels,et al.  DuP 747: sar study , 1992 .